财新传媒
财新英文 > 要闻 > 正文

In Depth: As Mass Covid Testing Becomes China’s New Normal, Debate Grows Over Who Pays

By Liu Denghui, Dong Hui and Zhang Yukun
2022年05月27日 13:05
National Healthcare Security Administration says local medical insurance funds shouldn’t be used for large-scale programs
A regular nucleic acid testing mandate across the country could cost around 1.8% of GDP, economists estimate. Photo: VCG

As China’s local governments rack up billions of yuan of health care costs to implement the country’s dynamic “zero-Covid” policy, including mass testing and vaccination campaigns, a debate is growing about where the money is coming from to pay for it all.

  [财新双语通产品,是为有双语需求读者专门订制的优惠产品, 按此可享超值优惠订阅。]

版面编辑:喻竹杨洋
财新私房课
好课推荐
财新微信